The company said it will use the funds to accelerate expansion of its MeMed BV test, which distinguishes between bacterial and viral infections.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
The company continues to move toward its planned merger with German diagnostics firm Curetis, which is expected to close early next year.
Hardy Diagnostics has partnered with NG Biotech to exclusively distribute the 15-minute test in the US. It has also brought it through the US regulatory process.
The NG-Test Carba 5 detects and differentiates KPC, OXA-48-like, VIM, IMP, and NDM and provides results in 15 minutes.
Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.
Specific Diagnostics said it plans to apply CE marking to the Reveal system next year, followed by submission to the FDA for 510(k) clearance.
Under the contract, which is worth up to $45 million, Selux is developing a technology for automated, high-throughput antimicrobial susceptibility testing.
The in vitro diagnostic company said it would use the financing to commercialize its antibiotic susceptibility platform called Reveal.
The combined firm will be based in Gaithersburg, Maryland and will focus on infectious disease diagnostics and antimicrobial resistance prediction services.